NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...

Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Political novice Renard Johnson's business acumen, community work brings new leadership style to mayor's office.

Coming into Monday trading, Intra-Cellular stock was up about 40% over the past 12 months. Write to Elsa Ohlen at ...

This fall, pharmaceutical and medical technology company Johnson & Johnson announced that a newly created Dallas subsidiary ...

Johnson & Johnson just announced a major acquisition to boost its position in the biopharmaceutical market. Quantum computing ...

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tim ...

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are ...

Ald. Raymond Lopez want to test a technology that helps police identify and respond to gunshots, but he needs city approval.

S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.